Bevacizumab plus paclitaxel/carboplatin is predicted to become the clinical gold-standard for advanced ovarian cancer in 2011

Source: Inpharma, Volume 1, Number 1637, 2008-05-10 , pp. 2-2(1)

Keywords: Bevacizumab, therapeutic use; Bristol-Myers-Squibb; Carboplatin, therapeutic use; Chugai-Pharmaceutical; Decision-Resources; Genentech; Healthcare-news; Ovarian-cancer, treatment; Paclitaxel, therapeutic use; Pharmaceutical-industry; Prescribing; Roche

Document Type: Short communication

Links for this article

http://www.ingentaconnect.com/adis/inp/2008/00000001/00001637/art00003
http://openurl.ingenta.com/content?genre=article&issn=1173-8324&volume=1&issue=1637&spage=2&epage=2